PNC Financial Services Group’s Taysha Gene Therapies TSHA Stock Holding History

PNC Financial Services Group’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.17K	Buy	1,053 +10	+1%	+$59	﹤0.01%	4243
2026 Q1	$4.66K	Sell	1,043 -11	-1%	-$51	﹤0.01%	4304
2025 Q4	$5.8K	Sell	1,054 -254	-19%	-$1.23K	﹤0.01%	4171
2025 Q3	$4.28K	Buy	1,308 +308	+31%	+$872	﹤0.01%	4268
2025 Q2	$2.31K	Hold	1,000	–	–	﹤0.01%	4373
2025 Q1	$1.39K	Hold	1,000	–	–	﹤0.01%	4447
2024 Q4	$1.73K	Hold	1,000	–	–	﹤0.01%	4317
2024 Q3	$2.01K	Hold	1,000	–	–	﹤0.01%	4289
2024 Q2	$2.24K	Buy	+1,000	New	+$2.91K	﹤0.01%	4226

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PNC Financial Services Group's TSHA Position: Q2 2026 in Review

PNC Financial Services Group increased its Taysha Gene Therapies (TSHA) stake by 0.96% in Q2 2026, buying an estimated $59 and bringing the position to 1,053 shares worth $7.17K. The position accounts for ﹤0.01% of the portfolio, ranked #4243.

PNC Financial Services Group first reported a position in TSHA in Q2 2024 and has held it in 9 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

PNC Financial Services Group held 1,053 shares of Taysha Gene Therapies worth $7.17K as of Q2 2026.
PNC Financial Services Group bought 10 Taysha Gene Therapies shares in Q2 2026, an estimated $59.
Taysha Gene Therapies made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4243 holding.
PNC Financial Services Group first reported a position in Taysha Gene Therapies in Q2 2024 and has held it in 9 quarters since.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.